CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Clinical trials for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) trials appear
Sign up with your email to follow new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for CIDP: modified antibody trial launches
Disease control Recruiting nowThis study tests TAK-411, a specially modified antibody, in 36 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), an autoimmune disease that attacks nerve coverings and causes muscle weakness. The goal is to see if TAK-411 can improve physical function …
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated May 17, 2026 06:18 UTC
-
New drug tested for nerve disorder maintenance
Disease control Recruiting nowThis study tests if a new drug, TAK-881, works as well as an existing treatment, HYQVIA, for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a nerve condition causing weakness and numbness. About 59 participants who already receive immunoglobulin the…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
CIDP patients switch to HyQvia: how does it really work?
Disease control Recruiting nowThis study follows 30 adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers will collect information from medical records, interviews, and questionnaires to understand why patients chose HyQvia, how sat…
Matched conditions: CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP)
Sponsor: Takeda • Aim: Disease control
Last updated May 13, 2026 15:59 UTC